New Pancreatic Cancer Drug Nearly Doubles Survival Daraxonrasib extended median survival to 13.2 months vs. 6.7 months with standard chemo, and eligible patients can now access the drug for free through an FDA expanded access program. Original Source: https://www.moneytalksnews.com/new-pancreatic-cancer-drug-nearly-doubles-survival/